Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rusnano’s Grand Ambitions In Biotech

This article was originally published in Start Up

Executive Summary

Now on the ground in Silicon Valley, Russian sovereign fund Rusnano is investing broadly in nanotechnology around the globe, and a lot of those rubles are flowing to US biotech firms, with one major stipulation: help bring innovation and jobs back to Mother Russia.

You may also be interested in...



Burrill & Co. Launches Fourth Fund With $313 Million And Aims For More

Fresh from an exceptional return on its investment in recently-acquired Pharmasset, the San Francisco firm already has enough to make Burrill Capital Fund IV its largest fund yet.

To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano

The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.

Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop

Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel